Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
6.260
+0.670 (+11.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
Next >
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
September 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
August 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
August 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
July 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
July 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
June 29, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
June 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
June 01, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
May 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2023 Annual General Meeting Results
May 17, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
May 09, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
May 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
May 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
April 28, 2023
From
Aurinia
Via
Business Wire
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
April 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
April 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
April 11, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
April 05, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
February 28, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
February 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
February 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
These 2 Healthcare Stocks Have Doubled in 2023
February 01, 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.
Via
MarketBeat
Aurinia Announces PTAB Has Terminated Inter Partes Review
January 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
January 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
January 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.